The cannabinoid CBD does not cause psychoactive effects, as opposed to tetrahydrocannabinol (THC) - the cannabinoid known to cause the psychoactive effects in cannabis.More news: Arsenal goalkeeper Cech proud after Dublin performance for Chelsea win
Pancreatic cancers begin when cells in the pancreas begin to multiply uncontrollably and form an abnormal and excessive tissue growth with the potential to spread to other parts of the body.
Lead researcher Professor Marco Falasca from Queen Mary University of London said: "This is a remarkable result".
While the current study only looked at the effect of CBD in mice, clinical trials in humans are needed to confirm whether or not CBD improves survival rates of pancreatic cancer patients, the researchers said.
In the research on mice, led by Dr. Ferro, the scientists observed that the gene dubbed as GPR55 is responsible for pancreatic cancer cells development.More news: Mandhana equals the record for fastest half-century in women's T20
At present, 9,800 people in the United Kingdom are diagnosed with pancreatic cancer and the illness has one of the lowest survival rates - about 5 per cent of those with the condition survive for five years, and around 80 per cent die within a year of diagnosis. This drug is made from cannabidiol.
CBD is already known to be helpful in easing symptoms of chemotherapy such as nausea and vomiting, so it has the potential to improve the quality of a patient's life as well as extend the length of it. Just over half the extracts were associated with a seizure reduction of 75-100 percent, which reinforces observations from animal studies and case reports of anticonvulsant effects of THC and THCA.
If these results could be replicated in humans, he adds, cannabidiol could be used immediately in cancer clinics, since it is already approved for use in clinics.
It also involved researchers from The Beatson Institute for Cancer Research in Scotland.More news: ANC ‘not undermining parliamentary processes’ on land - Godongwana
You can help support free, independent journalism for as little as 50p.